Mode
Text Size
Log in / Sign up

WHO reporting system provides balanced diagnostic accuracy for malignancy risk in lung lesionsWHO reporting system helps doctors identify lung cancer risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that the 'suspicious' or higher category provides a balanced balance of sensitivity and specificity for malignancy.

This meta-analysis evaluates the diagnostic accuracy of the WHO reporting system for lung cytopathology in patients undergoing fine-needle aspiration biopsy (FNAB). The analysis focuses on how different categories within the WHO framework correlate with malignancy risk and provide specific sensitivity and specificity metrics.

The findings indicate that the risk of malignancy increases from 27% in benign cases to 92% in malignant cases. For diagnostic accuracy, the 'malignant' category showed 33% sensitivity and 100% specificity. The 'suspicious' or higher category provided a balanced profile of 73% sensitivity and 96% specificity, while the 'atypical' or higher category yielded 83% sensitivity and 84% specificity.

A primary limitation noted is that the study evaluates a reporting system framework rather than a clinical intervention. The results suggest that the 'suspicious' or higher category provides the most balanced diagnostic utility for clinicians managing lung lesions. Clinical application depends on interpreting these categories as tools for risk stratification.

How this fits prior evidence

This meta-analysis addresses a gap in the standardized reporting of cytopathology for lung lesions. While prior coverage identified a 7.4% malignancy rate in new solid nodules and noted that pirfenidone reduces lung cancer incidence by 73% in certain IPF patients, this study focuses on the diagnostic accuracy of the WHO reporting system to stratify risk during biopsy procedures.

When a patient has a suspicious spot on their lung, doctors often use a needle to take a tiny sample. They then look at these cells under a microscope to see if they are cancerous. This process can be complex because some cells look unusual but aren't dangerous, while others might hide a serious disease.

A review of the WHO reporting system shows how well this standard helps doctors categorize those results. The study found that as the category moves from benign toward malignant, the risk of cancer increases significantly. Specifically, the 'suspicious' or higher category provides a strong balance for diagnosis, showing 73% sensitivity and 96% specificity.

While the system is a helpful tool for organizing data, it is important to remember that this study looks at how well the reporting system works, not at a new medical treatment. The goal is to provide doctors with a clearer way to categorize what they see under the microscope.

What this means for you:
The WHO reporting system helps doctors accurately categorize lung tissue samples to better identify cancer risks.

Common questions

How does the WHO reporting system help with lung cancer?

The system provides a way to categorize tissue samples based on how likely they are to be cancerous. For example, results labeled as 'suspicious' or higher show 73% sensitivity and 96% specificity. This helps doctors better understand the risk of malignancy when looking at lung lesions.

What is the accuracy of different categories in the system?

The risk of cancer increases as the category moves from benign to malignant, jumping from 27% to 92%. The 'atypical' or higher category shows 83% sensitivity and 84% specificity. These numbers help doctors balance how many cases they catch versus how many are incorrectly flagged.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
INTRODUCTION: The World Health Organization (WHO), together with the International Academy of Cytology and the International Agency for Research on Cancer, has introduced a standardized framework for reporting lung cytopathology. This approach clarifies diagnostic tiers, provides malignancy risk estimates, and integrates with the latest WHO Tumour Classification. Derived partly from the Papanicolaou Society of Cytopathology model, it strengthens diagnostic reproducibility and clinical risk categorization. The aim of this study is to evaluate the diagnostic accuracy of fine-needle aspiration biopsy (FNAB) in lung lesions reported under the WHO system. MATERIALS AND METHODS: A comprehensive search of Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov and conference abstracts was carried out using predefined terms ("lung," "diagnostic accuracy," "FNAB"). Studies applying the WHO reporting scheme to lung FNAB were eligible, with histopathology or clinical follow-up as reference standards. Meta-analysis examined sensitivity and specificity at 3 thresholds: (1) malignant only, (2) suspicious or higher, and (3) atypical or higher. Pooled diagnostic odds ratios and summary receiver operating characteristic analyses were undertaken. RESULTS: Four studies met inclusion criteria. Risk of malignancy increased across WHO categories, from 27% in benign to 92% in malignant. Sensitivity and specificity differed by cut-off: malignant only (33%, 100%), suspicious or higher (73%, 96%), atypical or higher (83%, 84%). Aggregate diagnostic odds ratios and summary receiver operating characteristic curves supported the diagnostic robustness of the system. CONCLUSIONS: The WHO reporting system provides effective stratification of lung FNABs. Defining positivity at "suspicious" or higher offers the best diagnostic balance, while including "atypical" increases sensitivity with minimal loss of specificity, supporting its clinical utility.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.